Payment overview · 2025
General Payments
$243.06
13 reported records · 7 companies
Healthcare provider profile · identity verified
Jonathan Scott Bremer, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ELIZABETHTON, TN · NPI 1336181239
Verified facts
What the public records show
CMS Open Payments records show Jonathan Scott Bremer, M.D. received $243.06 in general payments during 2025 across 13 reported records.
Lilly USA, LLC accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Ozempic by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $59.81 | 24.6% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $51.19 | 21.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.17 | 19.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.31 | 14.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.82 | 10.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.79 | 5.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.97 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $243.06 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $59.81 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $59.81 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $51.19 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.17 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.56 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 39 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
132 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
109 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 685 | 81 |
| Omeprazole | Omeprazole | 678 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 552 | 70 |
| Mirtazapine | Mirtazapine | 506 | 28 |
| Furosemide | Furosemide | 461 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 383 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 365 | 63 |
| Sertraline Hcl | Sertraline Hcl | 350 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 342 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 336 | 45 |
| Alprazolam | Alprazolam | 332 | 43 |
| Eliquis | Apixaban | 329 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 327 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 305 | 31 |
| Famotidine | Famotidine | 298 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 288 | 26 |
| Trazodone Hcl | Trazodone Hcl | 280 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 276 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 273 | 39 |
| Memantine Hcl | Memantine Hcl | 261 | 17 |
| Donepezil Hcl | Donepezil Hcl | 252 | 14 |
| Glipizide | Glipizide | 249 | 31 |
| Buspirone Hcl | Buspirone Hcl | 248 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 247 | 25 |
| Potassium Chloride | Potassium Chloride | 244 | 27 |
| Losartan Potassium | Losartan Potassium | 231 | 43 |
| Montelukast Sodium | Montelukast Sodium | 226 | 20 |
| Xarelto | Rivaroxaban | 226 | suppressed |
| Atenolol | Atenolol | 222 | 21 |
| Lisinopril | Lisinopril | 219 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 205 | suppressed |
| Gabapentin | Gabapentin | 184 | 32 |
| Tramadol Hcl | Tramadol Hcl | 181 | 34 |
| Lorazepam | Lorazepam | 180 | 23 |
| Metformin Hcl | Metformin Hcl | 153 | 37 |
| Prednisone | Prednisone | 151 | 76 |
| Midodrine Hcl | Midodrine Hcl | 142 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 135 | 14 |
| Valsartan | Valsartan | 135 | 25 |
| Myrbetriq | Mirabegron | 132 | suppressed |
| Meloxicam | Meloxicam | 129 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 115 | 14 |
| Jardiance | Empagliflozin | 109 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 26 |
| Venlafaxine Hcl | Venlafaxine Hcl | 104 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 94 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 94 | 38 |
| Paroxetine Hcl | Paroxetine Hcl | 86 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 84 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 79 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 77 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 23 |
| Divalproex Sodium | Divalproex Sodium | 72 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 70 | 14 |
| Simvastatin | Simvastatin | 68 | 18 |
| Metformin Hcl Er | Metformin Hcl | 64 | suppressed |
| Cephalexin | Cephalexin | 60 | 17 |
| Mounjaro | Tirzepatide | 59 | suppressed |
| Allopurinol | Allopurinol | 58 | 15 |
| Benazepril Hcl | Benazepril Hcl | 58 | suppressed |
| Lamotrigine | Lamotrigine | 58 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | suppressed |
| Finasteride | Finasteride | 55 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 53 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | suppressed |
| Ramipril | Ramipril | 53 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 48 | 16 |
| Sucralfate | Sucralfate | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 46 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 45 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 44 | suppressed |
| Azithromycin | Azithromycin | 44 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 13 |
| Folic Acid | Folic Acid | 41 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Ozempic | Semaglutide | 39 | 11 |
| Carvedilol | Carvedilol | 36 | 12 |
| Fluphenazine Hcl | Fluphenazine Hcl | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 33 | suppressed |
| Synthroid | Levothyroxine Sodium | 33 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 33 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 32 | suppressed |
| Estradiol | Estradiol | 30 | 12 |
| Nystatin | Nystatin | 30 | 13 |
| Linzess | Linaclotide | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | suppressed |
| Xifaxan | Rifaximin | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 22 |
| Ibuprofen | Ibuprofen | 28 | 11 |
| Methimazole | Methimazole | 28 | suppressed |
| Mirabegron Er | Mirabegron | 28 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 27 | 15 |
| Diazepam | Diazepam | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 15 |
| Amoxicillin | Amoxicillin | 25 | 23 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 25 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 18 |
| Metolazone | Metolazone | 24 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 21 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Gemtesa | Vibegron | 21 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 17 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Constulose | Lactulose | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Travoprost | Travoprost | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $243.06 · 13 records | Lilly USA, LLC | Kerendia, MOUNJARO, Ozempic, QULIPTA, Rybelsus, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error